Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor

Haematologica

Volumn 93, Issue 3, 2008, Pages 347-355

  Bruns, Ingmar ^a   Steidl, Ulrich ^b,c   Fischer, Johannes C ^a   Czibere, Akos ^a   Kobbe, Guido ^a   Raschke, Sascha ^a   Singh, Raminder ^a   Fenk, Roland ^a   Rosskopf, Michael ^a   Pechtel, Sabrina ^a   Von Haeseler, Arndt ^a,d   Wernet, Peter ^a   Tenen, Daniel G ^b   Haas, Rainer ^a   Kronenwett, Ralf ^a,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e SIEMENS AG   (Germany)

Author keywords

Autologous stem cell transplantation; Pegylated G CSF; Unconjugated G CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMEODOMAIN PROTEIN; IDARUBICIN; PROTEIN HOXA9; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD34 SELECTION; CELL CYCLE ARREST; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOFLUORESCENCE; LEUKAPHERESIS; MALE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE DRUG DOSE; STEM CELL; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; CELL CYCLE; CELL DIVISION; COLONY-FORMING UNITS ASSAY; FEMALE; FILGRASTIM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOMAGNETIC SEPARATION; LEUKAPHERESIS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 40849097536     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12081     Document Type: Article

References (53)

1. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.
2. Curran MP, Goa KL. Pegfilgrastim. Drugs 2002;62:1207-13.
3. Sarkar CA, Lowenhaupt K, Wang PJ, Horan T, Lauffenburger DA. Parsing the effects of binding, signaling, and trafficking on the mitogenic potencies of granulocyte colony-stimulating factor analogues. Biotechnol Prog 2003;19:955-64.
4. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003; 23:9-14.
5. Isidorins A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005;90:225-31.
6. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-6.
7. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T-cells and promotes transplantation tolerance. Blood 2004;103:3573-81.
8. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL¿combining dot below Blood 2006; 107:3430-5.
9. Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 2002;99:2037-44.
10. Neumann F, Teutsch N, Kliszewski S, Bork S, Steidl U, Brors B, et al. Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Phpositive CML in major molecular remission during therapy with imatinib. Leukemia 2005;19:458-60.
11. Kronenwett R, Graf T, Nedbal W, Weber M, Steidl U, Rohr UP, et al. Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. Cancer Gene Ther 2002;9:587-96.
12. Dolbeare F, Gratzner H, Pallavicini MG, Gray JW. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 1983;80:5573-7.
13. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 2002;99:11872-7.
14. Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood 1998;91:852-62.
15. Staal FJ, Cario G, Cazzaniga G, Haferlach T, Heuser M, Hofmann WK, et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 2006;20:1385-92.
16. Hodge D, Coghill E, Keys J, Maguire T, Hartmann B, McDowall A, et al. A global role for EKLF in definitive and primitive erythropoiesis. Blood 2006;107:3359-70.
17. Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res 2005;308:211-21.
18. Crooks GM, Fuller J, Petersen D, Izadi P, Malik P, Pattengale PK, et al. Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Blood 1999;94:519-28.
19. Ando K, Ajchenbaum-Cymbalista F, Griffin JD. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci USA 1993;90:9571-5.
20. Donato JL, Ko J, Kutok JL, Cheng T, Shirakawa T, Mao XQ, et al. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest 2002;109:51-8.
21. Furukawa Y. Cell cycle control genes and hematopoietic cell differentiation. Leuk Lymphoma 2002;43:225-31.
22. Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br J Haematol 2000;110:663-73.
23. Hirai H, Sherr CJ. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 1996;16:6457-67.
24. Abramovich C, Pineault N, Ohta H, Humphries RK. Hox genes: from leukemia to hematopoietic stem cell expansion. Ann N Y Acad Sci 2005;1044:109-16.
25. Azcoitia V, Aracil M, Martinez A, Torres M. The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo. Dev Biol 2005; 280: 307-20.
26. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ. Definitive hematopoiesis requires the mixedlineage leukemia gene. Dev Cell 2004;6:437-43.
27. Hisa T, Spence SE, Rachel RA, Fujita M, Nakamura T, Ward JM, et al. Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J 2004;23:450-9.
28. Lawrence HJ, Christensen J, Fong S, Hu YL, Weissman I, Sauvageau G, et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 2005;106:3988-94.
29. Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 2002;30:49-57.
30. Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, et al. Essential role of Jun family transcription factors in PU.1 knockdowninduced leukemic stem cells. Nat Genet 2006;38:1269-77.
31. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood 2005; 106: 1519-24.
32. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 2006;38:27-37.
33. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007;117:2611-20.
34. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-35.
35. Wilde CG, Griffith JE, Marra MN, Snable JL, Scott RW. Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J Biol Chem 1989;264:11200-3.
36. Ford AM, Bennett CA, Healy LE, Towatari M, Greaves MF, Enver T. Regulation of the myeloperoxidase enhancer binding proteins Pu1, CEBP alpha, -beta, and -delta during granulocyte-lineage specification. Proc Natl Acad Sci USA 1996;93:10838-43.
37. Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, Imanishi J, et al. C/EBPb is required for 'emergency' granulopoiesis. Nat Immunol 2006;7:732-9.
38. Khanna-Gupta A, Zibello T, Idone V, Sun H, Lekstrom-Himes J, Berliner N. Human neutrophil collagenase expression is C/EBP-dependent during myeloid development. Exp Hematol 2005;33:42-52.
39. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841-9.
40. Zhong JF, Zhao Y, Sutton S, Su A, Zhan Y, Zhu L, et al. Gene expression profile of murine long-term reconstituting vs. short-term reconstituting hematopoietic stem cells. Proc Natl Acad Sci USA 2005;102:2448-53.
41. Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006;34:382-8.
42. Fukuda S, Bian H, King AG, Pelus LM. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007;110:860-9.
43. Hess DA, Bonde J, Craft TP, Wirthlin L, Hohm S, Lahey R, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007;13:398-411.
44. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006;107:3772-8.
45. Fischer M, Schmidt M, Klingenberg S, Eaves CJ, von Kalle C, Glimm H. Short-term repopulating cells with myeloid potential in human mobilized peripheral blood do not have a side population (SP) phenotype. Blood 2006;108:2121-3.
46. Nibley WE, Spangrude GJ. Primitive stem cells alone mediate rapid marrow recovery and multilineage engraftment after transplantation. Bone Marrow Transplant 1998;21:345-54.
47. Nibley WE, Pohlmann SJ, Spangrude GJ. Patterns of organ-specific engraftment by stem cell subsets and committed progenitors. Stem Cells 1997;15 Suppl 1:31-9.
48. Zijlmans JM, Visser JW, Laterveer L, Kleiverda K, Heemskerk DP, Kluin PM, et al. The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. Proc Natl Acad Sci USA 1998;95:725-9.
49. Shojaei F, Trowbridge J, Gallacher L, Yuefei L, Goodale D, Karanu F, et al. Hierarchical and ontogenic positions serve to define the molecular basis of human hematopoietic stem cell behavior. Dev Cell 2005;8:651-63.
50. Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and Peg-G-CSF using a G-CSF-R KO model. Pharmacol Res 2004;50:55-8.
51. Hill GR, Morris ES, Fuery M, Hutchins C, Butler J, Grigg A, et al. Allogenic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006;12:603-7.
52. Kroschinsky F, Holig K, Platzbecker U, Poppe-Thiede K, Ordemann R, Blechschmidt M, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006;46:1417-23.
53. + cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors. Bone Marrow Transplant 2005;36:1027-31.